• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高滴度自失活γ-逆转录病毒载体生产细胞的产生

Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells.

作者信息

Ghani Karim, Boivin-Welch Michael, Roy Sylvie, Dakiw-Piaceski Angela, Barbier Martin, Pope Elena, Germain Lucie, Caruso Manuel

机构信息

CHU de Québec-Université Laval Research Center (Oncology Division), Université Laval Cancer Research Center, and Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC G1R 2J6, Canada.

CHU de Québec-Université Laval Research Center (Regenerative Medicine Division) and Centre de recherche en organogénèse expérimentale de l'Université Laval/LOEX, and Department of Surgery, Faculty of Medicine, Université Laval, Québec, QC, G1J 1Z4, Canada.

出版信息

Mol Ther Methods Clin Dev. 2019 Jun 7;14:90-99. doi: 10.1016/j.omtm.2019.05.013. eCollection 2019 Sep 13.

DOI:10.1016/j.omtm.2019.05.013
PMID:31312667
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6610700/
Abstract

The γ-retroviral vector is a gene delivery vehicle that is commonly used in gene therapy. Despite its efficacy, its strong enhancers contributed to malignant transformations in some hematopoietic stem cell (HSC) gene therapy trials. A safer version without viral enhancers (SIN) is available, but its production is cumbersome, as high titers can only be obtained in transient transfection. Our aim was to develop a system that could easily generate high-titer SIN vectors from stable producer cells. The use of the cytomegalovirus enhancer-promoter sequence to generate the full-length genomic RNA combined to sequences that decrease transcriptional readthrough (WPRE and strong polyadenylation sequences) led to 6 × 10 infectious units (IU)/mL of a SIN GFP vector in transient transfection. The incorporation of a blasticidin selection cassette to the retroviral plasmid allowed the generation of stable clones in the 293Vec packaging cells that release 2 × 10 IU/mL and 1.4 × 10 IU/mL of a SIN GFP and a SIN PIGA vector, respectively. A titer of 1.8 × 10 IU/mL was obtained with a SIN vector containing the long 8.9-kb COL7A1 cDNA. Thus, an efficient process was established for the generation of stable 293Vec-derived retrovirus producer cells that release high-titer SIN vectors.

摘要

γ-逆转录病毒载体是一种常用于基因治疗的基因递送工具。尽管其疗效显著,但其强大的增强子在一些造血干细胞(HSC)基因治疗试验中导致了恶性转化。有一种不含病毒增强子的更安全版本(自失活型,SIN),但其生产过程繁琐,因为只有通过瞬时转染才能获得高滴度。我们的目标是开发一种能够从稳定的生产细胞中轻松产生高滴度SIN载体的系统。使用巨细胞病毒增强子-启动子序列来产生全长基因组RNA,并结合减少转录通读的序列(土拨鼠肝炎病毒转录后调控元件,WPRE,和强聚腺苷酸化序列),在瞬时转染中产生了6×10感染单位(IU)/mL的SIN绿色荧光蛋白(GFP)载体。将杀稻瘟菌素选择盒整合到逆转录病毒质粒中,使得在293Vec包装细胞中产生稳定的克隆,分别释放2×10 IU/mL和1.4×10 IU/mL的SIN GFP载体和SIN磷酸肌醇聚糖A(PIGA)载体。对于一个含有8.9 kb长的Ⅶ型胶原基因(COL7A1)cDNA的SIN载体,获得了1.8×10 IU/mL的滴度。因此,建立了一个有效的方法来产生稳定的源自293Vec的逆转录病毒生产细胞,这些细胞可释放高滴度的SIN载体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/81df78725892/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/883e8c1f2186/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/33fd6479ae93/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/78cf3eb045e5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/8bdf3d3e680f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/83e0b14cebfa/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/81df78725892/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/883e8c1f2186/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/33fd6479ae93/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/78cf3eb045e5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/8bdf3d3e680f/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/83e0b14cebfa/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19df/6610700/81df78725892/gr6.jpg

相似文献

1
Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells.高滴度自失活γ-逆转录病毒载体生产细胞的产生
Mol Ther Methods Clin Dev. 2019 Jun 7;14:90-99. doi: 10.1016/j.omtm.2019.05.013. eCollection 2019 Sep 13.
2
HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA.基于人胚肾293细胞的γ-逆转录病毒(自失活)载体生产平台:用于安全高效转移Ⅶ型胶原蛋白α1链(COL7A1)互补DNA的应用
Hum Gene Ther Clin Dev. 2014 Dec;25(4):218-28. doi: 10.1089/humc.2014.083.
3
Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.利用piggyBac转座子构建用于生产临床级自失活γ-逆转录病毒载体的稳定包装细胞系。
Hum Gene Ther Methods. 2014 Aug;25(4):253-60. doi: 10.1089/hgtb.2014.071.
4
Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.通过串联阵列转染高效构建用于重症联合免疫缺陷症X1型(SCID-X1)基因治疗的自失活(SIN)慢病毒载体的生产细胞系。
Blood. 2009 May 21;113(21):5104-10. doi: 10.1182/blood-2008-11-191049. Epub 2009 Mar 13.
5
The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors.土拨鼠肝炎病毒转录后调控元件可减少逆转录病毒载体的通读转录。
Gene Ther. 2007 Sep;14(17):1298-304. doi: 10.1038/sj.gt.3302979. Epub 2007 Jun 28.
6
A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration.一种基于新 PG13 的包装细胞系,用于使用靶向整合稳定生产临床级自失活γ逆转录病毒载体。
Gene Ther. 2010 Feb;17(2):272-80. doi: 10.1038/gt.2009.134. Epub 2009 Oct 29.
7
Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.克服包装细胞中的启动子竞争可提高自失活逆转录病毒载体的产量。
Gene Ther. 2006 Nov;13(21):1524-33. doi: 10.1038/sj.gt.3302807. Epub 2006 Jun 8.
8
Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.使用单个自调控逆转录病毒盒快速生成四环素诱导型BCR-ABL缺陷逆转录病毒。
Leukemia. 2001 Oct;15(10):1658-62. doi: 10.1038/sj.leu.2402225.
9
A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.新一代逆转录病毒生产细胞:通过Flp介导的逆转录病毒载体位点特异性整合实现可预测且稳定的病毒生产
Mol Ther. 2006 Aug;14(2):285-92. doi: 10.1016/j.ymthe.2005.12.003. Epub 2006 May 11.
10
Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors.在293GPG包装细胞系中抑制组蛋白去乙酰化可提高自失活莫洛尼鼠白血病病毒衍生逆转录病毒载体的产量。
Virol J. 2006 Apr 7;3:27. doi: 10.1186/1743-422X-3-27.

引用本文的文献

1
An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell products.一种用于定量CAR-T细胞和TCR-T细胞产品中载体拷贝数的校正液滴数字PCR检测方法。
Immunooncol Technol. 2024 Dec 4;25:101031. doi: 10.1016/j.iotech.2024.101031. eCollection 2025 Mar.
2
The design of retroviral vectors used in the CAR-T products, risk management, and future perspective.嵌合抗原受体T细胞(CAR-T)产品中使用的逆转录病毒载体设计、风险管理及未来展望。
MedComm (2020). 2025 Jan 24;6(2):e70067. doi: 10.1002/mco2.70067. eCollection 2025 Feb.
3
A convenient viral transduction based method for advanced multi-engineering of primary human (CAR) T-cells.

本文引用的文献

1
GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.GMP 级别的 γδTCR 定义表达工程化 T 细胞的制造。
Front Immunol. 2018 May 30;9:1062. doi: 10.3389/fimmu.2018.01062. eCollection 2018.
2
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?嵌合抗原受体 T 细胞(CAR T 细胞)在癌症免疫治疗中的应用——产业的不断变化的目标?
Pharm Res. 2018 May 31;35(8):152. doi: 10.1007/s11095-018-2436-z.
3
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.输血依赖型β-地中海贫血症患者的基因治疗。
一种基于病毒转导的便捷方法,用于原代人(CAR)T细胞的高级多重工程改造。
J Genet Eng Biotechnol. 2024 Dec;22(4):100446. doi: 10.1016/j.jgeb.2024.100446. Epub 2024 Nov 28.
4
CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.针对头颈部鳞状细胞癌的靶向免疫治疗的 CD44v6 特异性 CAR-NK 细胞。
Front Immunol. 2023 Nov 10;14:1290488. doi: 10.3389/fimmu.2023.1290488. eCollection 2023.
5
Comparison of vector elements and process conditions in transient and stable suspension HEK293 platforms using SARS-CoV-2 receptor binding domain as a model protein.比较使用 SARS-CoV-2 受体结合域作为模型蛋白的瞬时和稳定悬浮 HEK293 平台中的载体元件和工艺条件。
BMC Biotechnol. 2023 Mar 7;23(1):7. doi: 10.1186/s12896-023-00777-7.
6
HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors.HEK293细胞系作为生产重组蛋白和病毒载体的平台。
Front Bioeng Biotechnol. 2021 Dec 13;9:796991. doi: 10.3389/fbioe.2021.796991. eCollection 2021.
7
Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy.植物病毒和噬菌体基诊断试剂与治疗试剂。
Annu Rev Virol. 2020 Sep 29;7(1):559-587. doi: 10.1146/annurev-virology-010720-052252.
8
Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.细胞治疗的非侵入性报告基因成像,包括 T 细胞和干细胞。
Mol Ther. 2020 Jun 3;28(6):1392-1416. doi: 10.1016/j.ymthe.2020.03.016. Epub 2020 Mar 20.
N Engl J Med. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342.
4
Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.基因治疗与组织工程联合治疗隐性营养不良型大疱性表皮松解症。
Eur Cell Mater. 2018 Feb 14;35:73-86. doi: 10.22203/eCM.v035a06.
5
Chimeric antigen receptor T-cell therapies for lymphoma.嵌合抗原受体 T 细胞疗法治疗淋巴瘤。
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46. doi: 10.1038/nrclinonc.2017.128. Epub 2017 Aug 31.
6
Twenty Years of European Union Support to Gene Therapy and Gene Transfer.欧盟支持基因治疗和基因转移二十年。
Hum Gene Ther. 2017 Nov;28(11):951-953. doi: 10.1089/hum.2017.110. Epub 2017 Jun 29.
7
Gene therapy for ADA-SCID, the first marketing approval of an gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.用于 ADA-SCID 的基因治疗,欧洲首个获得营销批准的基因治疗药物:为新一代先进治疗药物铺平道路。
EMBO Mol Med. 2017 Jun;9(6):737-740. doi: 10.15252/emmm.201707573.
8
Production of lentiviral vectors.慢病毒载体的生产。
Mol Ther Methods Clin Dev. 2016 Apr 13;3:16017. doi: 10.1038/mtm.2016.17. eCollection 2016.
9
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?X连锁重症联合免疫缺陷的基因治疗:我们目前的进展如何?
Hum Gene Ther. 2016 Feb;27(2):108-16. doi: 10.1089/hum.2015.137.
10
Progress and challenges in viral vector manufacturing.病毒载体生产的进展与挑战
Hum Mol Genet. 2016 Apr 15;25(R1):R42-52. doi: 10.1093/hmg/ddv451. Epub 2015 Oct 30.